Clinical trials: Infection, Coronavirus
COVID-19
Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers
This is a Phase 1, two-part, randomized, double blind, placebo controlled, ascending dose study to evaluate the safety, tolerability, pharmacokinetics of STI-1558 administered orally to healthy volunteers.
- Trial name
- NCT05364840
- Testing
- STI-1558
- Where
- Australia
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Sorrento Therapeutics, Inc.
COVID-19, Infectious Disease
A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine
The goal of this clinical trial is to learn about, test, and compare JCXH-221 in healthy volunteers. The main aims to answer are: To assess the safety and tolerability of the JCXH-221 vaccine in healthy adult subjects To identify…
- Trial name
- NCT05743335
- Testing
- JCXH-221
- Where
- 4 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Immorna Biotherapeutics, Inc.
COVID-19
CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany
This is a multicenter, observational, prospective, epidemiological cohort study at 45 hospitals in Germany, all part of a German hospital network. All hospitalized patients tested positive for SARS-CoV-2 will be included.
- Trial name
- CORONA Germany (NCT04659187)
- Where
- 8 sites in Germany
- Volunteers
- 4,000 people
- Sponsor
- Asklepios proresearch
COVID-19, Lymphocytopenia
InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort
Comparison of the effects of CYT107 vs Placebo administered IM at 10µg/kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.
- Trial name
- ILIAD-7-UK (NCT04379076)
- Testing
- Interleukin-7
- Where
- 13 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Revimmune
Relapsing Multiple Sclerosis (RMS)
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
This study evaluated if relapsing multiple sclerosis (MS) participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate immune response to the COVID-19 mRNA vaccine compared to…
- Trial name
- NCT04878211
- Testing
- Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Covid19
Niclosamide in COVID-19
This is a two-part, Phase 2, multicentre, randomized, double blind, 2-arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms
- Trial name
- NCT04542434
- Testing
- Niclosamide Oral Tablet
- Sponsor
- Entero Therapeutics
Communicable Disease, COVID-19
COVID-19 Diagnostic Self-testing Using Virtual Point-of-care
The goal of the research is to assess candidate COVID-19 rapid diagnostic tests (e.g. immunodiagnostic antibody tests, like Cellex qSARS-CoV-2 IgG/IgM Rapid Test, or antigen tests, like Turklab Test-It COVID-19 Home Test, AllBio…
- Conditions
- Communicable Disease, COVID-19, Sars-CoV2, Infectious Disease
- Trial name
- NCT04348864
- Testing
- COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support, Telemedicine
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Neuroganics LLC
COVID-19
Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
The purpose of the study is to evaluate the safety and immunogenicity of the investigational CpG 1018/Alum-adjuvanted recombinant SARS-CoV-2 trimeric spike (S)-protein subunit vaccine (SCB-2019) in adult participants with stable…
- Trial name
- COVID-19 (NCT05012787)
- Testing
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Havrix
- Where
- 4 sites in Ukraine
- Volunteers
- 1 people
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
A Strain Change Study for SARS-CoV-2 rS Vaccines
The present study aims to investigate the safety and immunogenicity of the Novavax JN.1 subvariant vaccine SARS-CoV-2 rS adjuvanted with Matrix-M (NVX CoV2705) in previously vaccinated adults.
- Trial name
- COVID-19 (NCT06409663)
- Testing
- NVX-CoV2705 Vaccine
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Novavax
Healthy
Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers
The Middle East Respiratory Syndrome Coronavirus (MERS CoV), a virus related to Severe Acute respiratory syndrome coronavirus (SARS CoV), was first recognized as a cause of severe pulmonary infection in 2012.
- Trial name
- NCT02670187
- Testing
- GLS-5300
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
SARS-CoV2 Infection
Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine
This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein…
- Trial name
- NCT06181292
- Testing
- PHH-1V81, Comirnaty Omicron XBB1.5
- Where
- 10 sites in Spain
- Volunteers
- 913 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Covid19
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19
This single-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 20 subjects aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in…
- Trial name
- NCT04663737
- Testing
- Silmitasertib, SOC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Senhwa Biosciences, Inc.
COVID-19
Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective in treating mild or moderate COVID-19 illness in adults and adolescents at highest risk for severe outcomes.
- Trial name
- NCT05157243
- Testing
- Nitazoxanide, Vitamin Super-B Complex, Standard of Care
- Sponsor
- Romark Laboratories L.C.
Severe COVID-19
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
The purpose of this Phase 2 study is to test safety, efficacy, and tolerability of an oral preparation of VB-201 in patients with severe COVID-19
- Trial name
- NCT04733833
- Testing
- VB-201 + Standard of care, Standard of care
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
COVID-19
Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)
This is a first in human, phase I, open-label, dose-escalation study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in healthy adults.
- Trial name
- NCT05113849
- Testing
- IN-B009 (Low-dose), IN-B009 (High-dose)
- Where
- 3 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Covid19
Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis
Clinical research study that evaluates the effect of Turkish Beam-Selective UV developed by RD GLOBAL ARAŞTIRMA GELİŞTİRME SAĞLIK İLAÇ İNŞAAT YATIRIMLARI A.Ş.
- Trial name
- NCT04642326
- Testing
- Test Group: experimental - UVC Therapy applied
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- RD Global Araştirma Geliştirme Sağlik Ilaç Inşaat Yatirimlari A.Ş.
COVID-19
A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)
A total of 516 healthy subjects aged 18 years and above who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine, will be enrolled, and randomly assigned to experimental group and control group in a 1:1…
- Trial name
- NCT05293548
- Testing
- Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09), Inactivated COVID-19 vaccine (Vero cells)
- Where
- United Arab Emirates
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
COVID-19
To Evaluate SSD8432/Ritonavir in Adults With COVID-19
This is a randomized, double-blind, placebo-controlled, phase II/III clinical study to evaluate the efficacy and safety of SSD8432 in combination with ritonavir in adult subjects with mild/common COVID-19.
- Trial name
- NCT05373433
- Testing
- SSD8432 750mg
- Volunteers
- 670 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Influenza A, Influenza B
Covid Flu A/B and RSV 4 in 1 Diagnostic Test
The goal of this observational study is to evaluate the diagnostic performance of an investigational Flu A/B, COVID-19 and RSV test in patients with signs and symptoms of respiratory infection.
- Conditions
- Influenza A, Influenza B, COVID - 19, RSV
- Trial name
- NCT07308158
- Testing
- Investigational Flu A/B Covid-19 and RSV Diagnostic Test
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 1,119 people
- Sponsor
- iHealth Labs inc
COVID-19, SARS-CoV-2
Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
The primary objective of this study is to assess the efficacy of early administration of ivermectin for three consecutive days to prevent SARS-CoV-2 hospitalisation in adults older than 50 years of age.
- Trial name
- NCT05993143
- Testing
- Ivermectin
- Where
- 20 sites in Spain
- Volunteers
- 249 people
- Sponsor
- Insud Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.